Bisoprolol STADA Arzneimittel AG: Uses, Dosage & Side Effects

What Is Bisoprolol STADA and What Is It Used For?

Bisoprolol fumarate belongs to a class of medications known as selective beta-1 adrenergic receptor antagonists, commonly referred to as cardioselective beta-blockers. Beta-blockers work by blocking the effects of certain stress hormones, primarily adrenaline (epinephrine) and noradrenaline (norepinephrine), on the heart. The beta-1 receptors are predominantly located in the heart muscle, and when these receptors are blocked by bisoprolol, the heart rate slows, the force of each heartbeat decreases, and blood pressure falls. This reduces the overall workload on the heart and its oxygen demand, which is the fundamental basis for the therapeutic effects of bisoprolol across all its approved indications.

What distinguishes bisoprolol from many other beta-blockers is its high degree of selectivity for beta-1 receptors over beta-2 receptors. Beta-2 receptors are found in the smooth muscle of the bronchi (airways) and peripheral blood vessels. Non-selective beta-blockers, such as propranolol, block both beta-1 and beta-2 receptors, which can cause bronchoconstriction and worsening of asthma or chronic obstructive pulmonary disease (COPD). Because bisoprolol preferentially targets beta-1 receptors at therapeutic doses, it has a lower propensity to cause respiratory side effects, although this cardioselectivity is not absolute and diminishes at higher doses.

The primary indications for bisoprolol, as recognized by major international regulatory agencies including the European Medicines Agency (EMA) and national medicines agencies, include:

• Chronic stable heart failure (CHF): Bisoprolol is indicated for the treatment of stable chronic heart failure with reduced systolic left ventricular function, in combination with angiotensin-converting enzyme (ACE) inhibitors, diuretics, and optionally cardiac glycosides (such as digoxin). The 1.25 mg tablet serves as the starting dose in the mandatory up-titration protocol. The evidence supporting bisoprolol in heart failure is robust: the CIBIS-II (Cardiac Insufficiency Bisoprolol Study II) trial, a landmark randomized controlled trial involving 2,647 patients, demonstrated a 34% reduction in all-cause mortality with bisoprolol compared to placebo in patients with NYHA class III-IV heart failure.
• Hypertension (high blood pressure): Bisoprolol effectively lowers blood pressure by reducing cardiac output and, over time, through reduction of peripheral vascular resistance. It can be used as monotherapy or in combination with other antihypertensive agents. The European Society of Cardiology (ESC) and European Society of Hypertension (ESH) guidelines recognize beta-blockers as appropriate first-line treatment for hypertension, particularly in patients with concomitant conditions such as heart failure, angina, or atrial fibrillation.
• Stable angina pectoris: By reducing heart rate and myocardial contractility, bisoprolol decreases the heart’s oxygen demand during exertion, thereby preventing or reducing the frequency of angina episodes. Beta-blockers are considered first-line antianginal therapy in the ESC guidelines for chronic coronary syndromes.

Bisoprolol has favorable pharmacokinetic properties that support once-daily dosing. After oral administration, it is almost completely absorbed from the gastrointestinal tract with a bioavailability of approximately 90%, meaning that the vast majority of the ingested dose reaches the systemic circulation. The plasma half-life is 10 to 12 hours, and elimination occurs equally through hepatic metabolism (approximately 50%) and renal excretion of unchanged drug (approximately 50%). This balanced elimination profile means that bisoprolol does not require dose adjustment in patients with mild-to-moderate hepatic or renal impairment, making it versatile in clinical practice.

What Should You Know Before Taking Bisoprolol STADA?

Contraindications

Bisoprolol must not be used in certain clinical situations where the risks clearly outweigh any potential benefit. Understanding these contraindications is critical for safe prescribing and use of the medication. The following conditions represent absolute contraindications to bisoprolol therapy:

• Hypersensitivity: Known allergy to bisoprolol fumarate or any of the excipients in the formulation. Allergic reactions to beta-blockers, while uncommon, can range from skin rashes to severe anaphylactic reactions.
• Acute heart failure or decompensated heart failure: Bisoprolol is indicated only for stable chronic heart failure. In acute heart failure or during episodes of decompensation requiring intravenous inotropic therapy, bisoprolol should not be initiated or continued, as further reduction in cardiac output could be dangerous.
• Cardiogenic shock: A life-threatening condition where the heart cannot pump enough blood to meet the body’s needs. Beta-blockers would worsen this condition by further depressing cardiac function.
• Second- or third-degree atrioventricular (AV) block: Without a functioning pacemaker, bisoprolol’s effect on slowing AV conduction could lead to complete heart block and cardiac arrest.
• Sick sinus syndrome: Unless the patient has a permanent pacemaker, as bisoprolol could cause severe bradycardia or asystole.
• Sinoatrial block: Similar to sick sinus syndrome, impaired conduction from the sinus node to the atria could be critically worsened by bisoprolol.
• Severe bradycardia (heart rate below 50-60 beats per minute before treatment): Bisoprolol would further slow the heart rate, potentially to dangerously low levels.
• Severe hypotension (systolic blood pressure below 90-100 mmHg): Further blood pressure reduction could compromise organ perfusion.
• Severe bronchial asthma or severe chronic obstructive pulmonary disease (COPD): While bisoprolol is cardioselective, very severe airways disease represents a contraindication due to the residual risk of bronchospasm.
• Late stages of peripheral arterial occlusive disease (Raynaud’s syndrome): Beta-blockers may worsen peripheral circulatory symptoms.
• Untreated pheochromocytoma: A rare adrenal gland tumor that produces excess catecholamines. Beta-blocker therapy without prior alpha-blockade can cause a paradoxical hypertensive crisis.
• Metabolic acidosis: Acidosis impairs myocardial responsiveness to catecholamines, and further beta-blockade can precipitate cardiovascular collapse.

Warnings and Precautions

Several conditions require special caution and close medical monitoring when bisoprolol is used. In these situations, the prescribing physician will carefully weigh the benefits against the risks and may adjust the dose or monitoring frequency accordingly:

• Diabetes mellitus: Bisoprolol may mask the symptoms of hypoglycemia (low blood sugar), particularly tachycardia and tremor. Sweating, a catecholamine-independent symptom, is typically not masked. Patients with diabetes should monitor their blood glucose levels more frequently when starting or adjusting bisoprolol therapy. The dose of antidiabetic medications may need to be adjusted.
• Strict fasting: Similar to diabetes, patients undergoing prolonged fasting may be at increased risk of hypoglycemia, and the warning signs may be masked by bisoprolol.
• First-degree AV block: Bisoprolol slows atrioventricular conduction and should be used with caution in patients with a pre-existing first-degree AV block.
• Prinzmetal’s (variant) angina: Beta-blockers may increase the frequency and duration of vasospastic angina episodes due to unopposed alpha-receptor-mediated coronary vasoconstriction. Cardioselective agents like bisoprolol carry a lower risk, but caution is still advised.
• Mild-to-moderate bronchial asthma or COPD: Although bisoprolol’s cardioselectivity provides an advantage over non-selective beta-blockers, patients with respiratory conditions should be monitored for signs of bronchospasm. Concomitant bronchodilator therapy may be advisable. In patients with mild-to-moderate obstructive airways disease, bisoprolol should be initiated at the lowest available dose with careful observation of respiratory function.
• Psoriasis or history of psoriasis: Beta-blockers have been reported to exacerbate psoriasis. Bisoprolol should only be used in these patients after careful consideration of the benefit-risk ratio.
• Pheochromocytoma (treated): In patients with a confirmed pheochromocytoma that has been adequately treated with alpha-blockers, bisoprolol may be cautiously introduced. However, treatment should always be combined with ongoing alpha-blockade.
• Thyrotoxicosis: Beta-blockers may mask the cardiovascular signs of thyrotoxicosis (overactive thyroid), particularly tachycardia. Abrupt withdrawal of beta-blockers in thyrotoxic patients may precipitate a thyroid storm.
• General anesthesia: If a patient taking bisoprolol is scheduled for surgery requiring general anesthesia, the anesthetist must be informed. The continuation or discontinuation of bisoprolol perioperatively is a clinical decision that depends on the specific circumstances. In general, abrupt withdrawal before surgery is not recommended due to the risk of rebound effects.

Pregnancy and Breastfeeding

Bisoprolol is generally not recommended during pregnancy unless the potential benefit to the mother justifies the potential risk to the fetus. Beta-blockers, as a class, can reduce placental perfusion (blood flow to the placenta), which may result in intrauterine growth restriction, premature delivery, or intrauterine death. Additionally, adverse effects such as bradycardia (slow heart rate) and hypoglycemia (low blood sugar) may occur in the fetus or newborn. If treatment with bisoprolol is considered necessary during pregnancy, uteroplacental blood flow and fetal growth should be monitored carefully. If harmful effects occur, alternative treatment should be considered.

It is not known whether bisoprolol is excreted in human breast milk. However, there is limited data suggesting some beta-blockers may appear in breast milk in small amounts. Therefore, breastfeeding is generally not recommended during treatment with bisoprolol. If breastfeeding is considered, the infant should be closely monitored for signs of beta-blockade, including low heart rate, low blood pressure, and respiratory difficulties.

Women of childbearing potential should discuss effective contraceptive measures with their healthcare provider before starting bisoprolol therapy. If pregnancy is planned, the treating physician should evaluate whether bisoprolol can be safely discontinued or switched to an alternative antihypertensive or heart failure medication with a more established safety profile in pregnancy, such as methyldopa or labetalol for hypertension.

How Does Bisoprolol Interact with Other Drugs?

Drug interactions with bisoprolol are clinically significant because they can either amplify or diminish the drug’s effects, sometimes with serious consequences. The additive effect on heart rate reduction and blood pressure lowering is the most common type of interaction encountered. Understanding these interactions is essential for both healthcare professionals and patients to ensure safe and effective treatment.

The following table summarizes the most important drug interactions with bisoprolol. The severity classifications are based on clinical significance and the potential for serious adverse outcomes.

Major Interactions

The most clinically dangerous interactions with bisoprolol involve other drugs that significantly slow the heart rate or depress cardiac conduction. The combination of bisoprolol with non-dihydropyridine calcium channel blockers, specifically verapamil and diltiazem, is particularly hazardous. Both drug classes reduce heart rate, slow atrioventricular (AV) conduction, and decrease myocardial contractility. When combined, these effects can be synergistic rather than simply additive, leading to severe bradycardia (dangerously slow heart rate), complete heart block (failure of electrical impulses to travel from the atria to the ventricles), profound hypotension, and acute heart failure. Intravenous administration of verapamil or diltiazem in a patient already receiving a beta-blocker is especially dangerous and should be avoided except in highly monitored settings.

The interaction with clonidine (a centrally acting antihypertensive) is unique and deserves special attention. If both bisoprolol and clonidine are being taken and clonidine is abruptly discontinued, the resulting rebound hypertension can be significantly amplified by the ongoing beta-blockade (because beta-blockers block the vasodilatory beta-2 receptors, leaving alpha-mediated vasoconstriction unopposed). For this reason, if both drugs must be stopped, bisoprolol should be discontinued first, followed by gradual tapering of clonidine several days later.

Class I antiarrhythmic drugs (such as flecainide, disopyramide, and quinidine) can potentiate the negative inotropic (heart-weakening) and negative dromotropic (conduction-slowing) effects of bisoprolol. This combination increases the risk of heart failure decompensation and bradyarrhythmias and should only be used under close cardiac monitoring. Similarly, amiodarone (a class III antiarrhythmic) can significantly prolong AV conduction when combined with bisoprolol.

Minor Interactions

Several other medications can interact with bisoprolol in ways that are generally manageable but still require awareness. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen may reduce the blood-pressure-lowering effectiveness of bisoprolol through their effects on sodium and water retention. Patients using NSAIDs regularly should have their blood pressure monitored, and paracetamol (acetaminophen) may be considered as an alternative analgesic when appropriate.

Rifampicin, a potent inducer of hepatic cytochrome P450 enzymes (particularly CYP3A4 and CYP2D6), can increase the metabolic clearance of bisoprolol, potentially reducing its plasma levels and therapeutic efficacy. Dose adjustments may be necessary in patients receiving rifampicin. Parasympathomimetic drugs (cholinesterase inhibitors) used in conditions such as Alzheimer’s disease or myasthenia gravis can increase the risk of bradycardia when combined with bisoprolol. Topical beta-blockers for glaucoma (such as timolol eye drops) may add to the systemic beta-blocking effects of bisoprolol, and patients using both should be monitored for additive effects on heart rate and blood pressure.

What Is the Correct Dosage of Bisoprolol STADA?

The dosage of bisoprolol depends on the clinical indication, the individual patient’s response, and the presence of any comorbid conditions that may necessitate dose adjustments. The general principle for all indications is to start at a low dose and increase gradually (up-titration), allowing the body to adapt to the medication’s effects on heart rate and blood pressure. Bisoprolol should be taken once daily, preferably in the morning, with or without food. The tablets should be swallowed whole with a glass of water and should not be crushed or chewed.

Adults

For hypertension and stable angina in adults, treatment is typically initiated at 5 mg once daily. If the blood pressure or angina control is inadequate after 1 to 2 weeks, the dose can be increased to 10 mg once daily. In some patients, particularly those with resistant hypertension, the dose may be increased up to a maximum of 20 mg once daily, although doses above 10 mg are rarely required and are used at the physician’s discretion. For the treatment of chronic stable heart failure, the starting dose is 1.25 mg once daily (which is the strength provided by this specific STADA formulation). The dose is then gradually increased in a stepwise manner over several weeks to months. Each dose increase should only occur after the patient has been stable on the current dose for at least 1 to 2 weeks. During up-titration, patients must be monitored for worsening heart failure, hypotension, and bradycardia.

Children

Bisoprolol is not recommended for use in children and adolescents under 18 years of age due to the lack of sufficient data on safety and efficacy in this population. The pharmacokinetics, optimal dosing, and long-term effects of bisoprolol in pediatric patients have not been adequately studied. In the rare instances where beta-blocker therapy is required for pediatric cardiovascular conditions, other beta-blockers with established pediatric dosing guidelines are preferred, and the decision to use any beta-blocker in children should be made by a pediatric cardiologist.

Elderly

No specific dose adjustment is generally required in elderly patients. However, older adults are often more susceptible to the effects of beta-blockers, including bradycardia, hypotension, and dizziness. The risk of falls related to orthostatic hypotension (a sudden drop in blood pressure upon standing) is particularly relevant in the elderly. Therefore, it is prudent to start at the lower end of the recommended dosing range and titrate upward more slowly, with frequent monitoring of heart rate, blood pressure, and symptoms. Elderly patients also have a higher prevalence of renal and hepatic impairment, which may warrant additional caution.

Missed Dose

If you forget to take your bisoprolol tablet at the usual time, take it as soon as you remember, unless it is close to the time for your next scheduled dose. In that case, skip the missed dose and take your next dose at the regular time. Do not take a double dose to make up for a missed one. If you frequently forget to take your medication, consider setting a daily alarm or using a pill organizer to help maintain consistency. Regular, uninterrupted dosing is important for optimal therapeutic benefit, particularly in heart failure where maintaining stable plasma levels helps prevent symptom fluctuations.

Overdose

An overdose of bisoprolol can be a serious medical emergency. The most common signs and symptoms of beta-blocker overdose include severe bradycardia (very slow heart rate), profound hypotension (dangerously low blood pressure), bronchospasm (constriction of the airways), acute heart failure, and in severe cases, cardiogenic shock. Hypoglycemia (low blood sugar) may also occur, particularly in children or patients with diabetes. If an overdose is suspected, emergency medical services should be contacted immediately.

Treatment of bisoprolol overdose is primarily supportive and symptomatic. In the hospital setting, management may include atropine for bradycardia, intravenous glucagon (which stimulates the heart through a mechanism independent of beta-receptors), intravenous fluids and vasopressors for hypotension, beta-2 agonist bronchodilators (such as salbutamol) for bronchospasm, and in refractory cases, temporary cardiac pacing or extracorporeal circulatory support. Gastric lavage and activated charcoal may be considered if the patient presents within 1 to 2 hours of ingestion.

What Are the Side Effects of Bisoprolol STADA?

Like all medications, bisoprolol can cause side effects, although not everyone experiences them. The side effects of bisoprolol are largely related to its pharmacological mechanism of action—blocking beta-1 adrenergic receptors in the heart and, to a lesser extent at higher doses, beta-2 receptors in other organs. Side effects tend to be dose-dependent, meaning they are more likely to occur and more severe at higher doses. Many side effects are most prominent at the beginning of treatment or following dose increases and may improve as the body adjusts to the medication. The side effects are classified below according to their frequency of occurrence, based on data from clinical trials and post-marketing surveillance.

It is important to understand that the side effect profile during heart failure treatment initiation may differ from that seen in hypertension treatment. When bisoprolol is started for heart failure, transient worsening of heart failure symptoms (such as increased shortness of breath, fluid retention, or fatigue) is relatively common during the initial titration phase. This occurs because the heart is already compromised, and the acute reduction in sympathetic support from beta-blockade can temporarily decrease cardiac output. However, this initial deterioration is typically manageable with temporary dose reduction or adjustment of concomitant heart failure medications (particularly diuretics), and the long-term benefits of continued beta-blocker therapy in heart failure far outweigh these short-term risks.

Patients should report any new, persistent, or worsening symptoms to their healthcare provider. In particular, seek immediate medical attention if you experience severe dizziness or fainting, resting heart rate below 50 beats per minute, difficulty breathing or wheezing, sudden weight gain (more than 2 kg in a few days, suggesting fluid retention), chest pain, or signs of a severe allergic reaction (swelling of the face, lips, tongue, or throat; difficulty breathing; severe skin rash).

How Should You Store Bisoprolol STADA?

Proper storage of medications is essential to maintain their effectiveness and safety throughout their shelf life. Bisoprolol STADA film-coated tablets should be stored at room temperature, which is generally considered to be below 25°C (77°F). Avoid storing the medication in places that are subject to extreme temperatures, such as bathrooms (where humidity is high), near windows with direct sunlight, or in cars during hot weather. The film coating on the tablets provides some protection against environmental factors, but prolonged exposure to heat or moisture can still degrade the active ingredient.

Keep the tablets in their original blister packaging until ready to use, as the blister pack provides an additional barrier against moisture and light. Do not transfer tablets to a different container unless it provides equivalent protection. The expiry date printed on the packaging (typically on the blister and the outer carton) indicates the last date by which the medication is guaranteed to retain its full potency and quality. Do not use bisoprolol after this date, even if the tablets appear visually unchanged.

As with all medications, bisoprolol must be kept out of the sight and reach of children. Beta-blocker overdose can be particularly dangerous in children, as they are more susceptible to the cardiovascular and metabolic effects (especially hypoglycemia). If there are young children in the household, consider using a child-proof medication cabinet or lockbox. Do not dispose of unused or expired medications in household waste or down the drain. Return them to a pharmacy for proper disposal in accordance with local regulations, as pharmaceutical waste can contaminate water supplies and harm the environment.

What Does Bisoprolol STADA Contain?

Understanding the complete composition of a medication is important for several reasons. Patients with known allergies or intolerances to specific excipients need this information to avoid adverse reactions. Additionally, the excipient profile can be relevant for patients with conditions such as lactose intolerance or celiac disease. The composition of Bisoprolol STADA 1.25 mg film-coated tablets is described below.

Active Ingredient

Each film-coated tablet contains 1.25 mg of bisoprolol fumarate, equivalent to approximately 1.07 mg of bisoprolol base. Bisoprolol fumarate is a white to off-white crystalline powder that is soluble in water and methanol. The fumarate salt form was chosen because of its excellent water solubility, which ensures reliable and consistent absorption from the gastrointestinal tract. Bisoprolol fumarate has the chemical formula C₁₈H₃₁NO₄·C₄H₄O₄ and a molecular weight of 766.97 g/mol (for the hemifumarate) or 325.44 g/mol (for the bisoprolol base).

Inactive Ingredients (Excipients)

The excipients used in the tablet core and film coating serve various pharmaceutical purposes including binding, filling, lubricating, and coating the tablet. The exact excipient composition may vary slightly between batches and markets, but typical excipients found in bisoprolol film-coated tablets from STADA and similar generic formulations include:

• Microcrystalline cellulose: A common tablet filler and binder derived from plant cellulose. It provides structural integrity to the tablet and aids in uniform drug distribution.
• Calcium hydrogen phosphate (anhydrous or dihydrate): A filler that adds bulk to the tablet and contributes to consistent tablet weight and hardness.
• Maize starch (corn starch): Functions as a disintegrant, helping the tablet break apart in the gastrointestinal tract for proper drug release.
• Croscarmellose sodium: A superdisintegrant that rapidly absorbs water and swells, facilitating fast disintegration of the tablet.
• Colloidal anhydrous silica (silicon dioxide): A glidant that improves the flow properties of the powder blend during manufacturing.
• Magnesium stearate: A lubricant that prevents the tablet material from sticking to the manufacturing equipment during compression.
• Film-coating components: The film coating typically consists of hypromellose (hydroxypropyl methylcellulose), titanium dioxide (white pigment), macrogol (polyethylene glycol, as plasticizer), and may include iron oxide pigments for coloring.

Patients with known lactose intolerance should note that some bisoprolol formulations contain lactose monohydrate as an excipient; however, the specific STADA formulation should be checked against the patient information leaflet provided with each pack for the definitive list of excipients. If you are unsure about any ingredient, consult your pharmacist. The film coating is designed to make the tablet easier to swallow and to protect the active ingredient from degradation by light and moisture. It does not affect the rate or extent of drug absorption.